High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 51-57

  Bethke, T D ^a   Lahu, G ^a  

^a Nycomed GmbH   (Germany)

Author keywords

Bioavailability; Pharmacokinetics; Phase I; Phosphodiesterase 4; Roflumilast

Indexed keywords

DRUG METABOLITE; ROFLUMILAST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; INTESTINE WALL; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYCLOPROPANES; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 78650847033     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49051     Document Type: Article

References (13)

1. Bethke TD, Böhmer G, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter C. Dose-proportional intra-individual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007; 47: 26-36. (Pubitemid 44973995)
2. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001; 297: 280-290.
3. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ for the M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-694.
4. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF for the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374: 695-703.
5. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007; 62: 1081-1087. (Pubitemid 350206202)
6. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001; 297: 267-279. (Pubitemid 32242587)
7. Hauns B, Hermann R, Hünnemeyer A, Herzog R, Hauschke D, Zech K, Bethke TD. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily, phosphodiesterase 4 inhibitor in healthy subjects. J Clin Pharmacol. 2006; 46: 1146-1153. (Pubitemid 44387414)
8. Investigator's Brochure Roflumilast. Version 10. ALTANA Pharma, 2007.
9. Manegold A, Hauns B, David M, Zech K, Bethke TD, Wurst W. Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500 μg to 1,000 μg are dose-linear in healthy subjects. Eur Respir J. 2002; 20 (Suppl): 108.
10. Nassr N, Huennemeyer A, Herzog R, von Richter O, Hermann R, Koch M, Duffy K, Zech K, Lahu G. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol. 2009; 68: 580-587.
11. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
12. Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008; 55: 308-315.
13. von Richter O, Lahu G, Huennemeyer A, Herzog R, Zech K, Hermann R. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007; 46: 613-622. (Pubitemid 47025361)